Myovant Sciences (MYOV) Acquired by Sumitomo Pharma for $27/sh or Company Value of $2.9B Oct 24, 2022 05:54AM
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement Oct 23, 2022 11:36PM
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement Oct 23, 2022 11:36PM
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement Oct 23, 2022 11:30PM
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019 Feb 10, 2020 08:30AM


Dec 30, 2019 05:15PM Form 3 Myovant Sciences Ltd. For: Dec 27 Filed by: Nomura Hiroshi
Dec 30, 2019 08:30AM Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
Dec 30, 2019 08:30AM Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
Oct 31, 2019 09:20AM Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
Oct 31, 2019 09:20AM Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders